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Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic
groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the
Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In
this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive
drug reactions induced by different drugs, as have been found in different populations, and to summarize
the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLAB*57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1% to 3%, and
HLA-DPB1*03:01 prevalence, associated with aspirin-induced asthma, ranges from 10% to 14% in the
GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the
discovery of new associations, confirm ones found with a low evidence rate and enable cost–effectiveness
analysis of allele screening before drug use.
Tweetable abstract: What is known about HLA alleles and drug hypersensitivity associations in the
populations of North Africa and the Middle East and the potentiality of genomic tools and projects to
propose possible opportunities.
First draft submitted: 14 June 2022; Accepted for publication: 27 July 2022; Published online:
16 August 2022
Keywords: adverse drug reactions • drug hypersensitivity • Greater Middle East • HLA pharmacogenomic

associations • HLA polymorphism

In a global concerted effort toward personalizing medicine using genome information, pharmacogenomics has
become mainstream. It is the discipline of studying an individual’s genetic characteristics underlying drug efficacy
or adverse drug reactions. Adverse drug reactions (ADRs) are defined by the WHO as:
“a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis,
diagnosis, or therapy of disease or for modification of physiological function” [1].
ADRs are broadly classified as type A reactions (augmented pharmacologic effects) or type B reactions (bizarre or
idiosyncratic reactions). Type A ADRs are predictable, dose dependent and related to the pharmacologic activity of
the drug (e.g., bleeding related to the anticoagulant warfarin), whereas type B ADRs, also known as hypersensitive
drug reactions (HDRs) or idiosyncratic adverse drug reactions, are not an extension of the drug’s pharmacologic
effect are generally dose independent unpredictable and result from interactions between a pharmacologic agent and
the human immune system (e.g., abacavir hypersensitivity or anaphylaxis to penicillin) [1–3]. Studies have reported
variable percentages of hospitalization related to the different types of ADRs, ranging from 3.5% to 15%, based on
studies conducted in Europe and the USA [4,5]. Along with morbidity and mortality, ADRs represent a financial
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burden to healthcare providers, as they are associated with prolonged length of stay and subsequent increase in the
cost of hospitalization [4,5]. ADRs also confer a financial burden on the pharmaceutical industry as a leading cause
of drug withdrawal from the market [6].
Although type B reactions account for only 15–30% of ADRs, they present more severe reactions than type
A reactions, leading to significant morbidity, mortality and socioeconomic burden [3]. The most common HDRs
include cutaneous adverse drug reactions. Examples of life-threatening severe cutaneous adverse reactions include
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reactions with eosinophilia and
systemic symptoms (DRESS).
For over 30 years, multiple reports have shown that life-threatening HDRs are associated with specific alleles
of the HLAs on the short arm of chromosome 6, considering their role in peptide presentation in the adaptive
immune response. The genes within the human MHC – in particular, those that encode the MHC class I and
MHC class II – that are highly polymorphic, [7,8] and variants potentially code isoforms that may modulate the
response. Alternatively, since the genes of the MHC are in tight linkage disequilibrium [7], candidates within
specific haplotypes may be involved. The carriage rate of HLA alleles differs among populations and across different
geographic areas [9]. Infectious agents and epidemics in the world regions may have played a main role in the
selective pressure behind HLA polymorphism and variability across the globe. Therefore, it is not surprising that
HLA-ADR association reports have varied in different populations [10].
Several HLA alleles have been proposed as valid genetic markers for preventing life-threatening reactions,
mainly in Asian and Western populations, where studies have confirmed HLA-HDR associations [11–13]. By
establishing these markers, it may be possible to avoid some drug-induced immune reactions. For not yet wellstudied populations, information about the frequencies of these pharmacogenetic HLA alleles, robustly involved
in hypersensitive reactions, may present a first step toward associations to be studied in a specific population.
Association studies should then be conducted in the specific population to confirm the HLA allele-HDR association
and to determine the relative positive and negative predictive value of HLA allele screening before drug use.
Consequently, cost–effectiveness or the cost–utility analysis, based on determined predictive values in a specific
population, would address the clinical implementation of allele screening tests.
In this regard, this review summarizes the frequencies of HLA alleles, strongly associated with ADRs, in the
different populations of the Greater Middle East (GME) and discusses the potentiality of using HLA alleles as
pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the GME.

Immunopathogenesis of HLA-mediated hypersensitivity drug reactions
The HLA class I (HLA-A, -C and -B) and class II (HLA-DRA1, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DP1
and HLA-DPB1) genes encode the MHC class I and class II proteins, respectively. Those cell surface proteins regulate
the immune response by distinguishing the body’s own proteins (self ) from foreign proteins (nonself ) through
peptides presentations. HLA genes are known to be highly polymorphic within and across human populations.
This polymorphism accounts for the diversity in protein variant, especially within the peptide-binding groove that
subsequently controls the adaptive immune system interaction.
Drug molecules and reactive metabolites could result in subsequent T-cell-mediated immune reactivity involving
HLA molecule antigen presentation. In some cases, the interaction between the patient’s specific MHC molecules
and the drug molecules can induce ADRs through CD8+ (MHC class I) and/or CD4+ (MHC class II) T-cellmediated reactions, even though the precise mechanisms at the molecular level of HLA–drug interactions are still
poorly understood [14,15].
Three main models potentially explain the immune-pathogenesis of ADRs with human MHC molecules:
the hapten/prohapten model, the altered peptide repertoire model and the pharmacologic interaction model
(Figure 1) [13].
In the hapten/prohapten model, the ADR results from covalent binding of the drug to an endogenous cellprotein, forming a complex of drug-haptenized peptide, presented then at the cell surface by the MHC molecule.
The drug–protein complex is then recognized by T-cell receptors on T cells and initiates the innate immune
system [16]. In the altered peptide repertoire model, the HDR results from noncovalent binding of the drug and a
self-peptide or a drug-induced self-peptide with MHC molecules recognized therefore as foreign by T cells [17]. In
the pharmacologic interaction model, the HDR results from a noncovalent interaction between the drug molecules
and HLA, creating neoantigens, which will result in a T-cell-mediated immune reaction [18].
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Figure 1. Immunopathogenic models of MHC adverse drug reactions. (A) Hapten/prohapten model: adverse drug
reactions are caused by a drug metabolite forming a covalent bond with an endogenous protein, which is then
presented by the MHC. (B) Altered protein repertoire model: the drug molecule noncovalently binds with an altered
self-peptide to the MHC, causing a change in its binding cleft, causing T cells to recognize the peptide as foreign. (C)
Pharmacologic interaction model: the drug molecule forms a noncovalent bond directly with the T-cell receptor or
the MHCs, which results in T-cell activation.
TCR: T-cell receptor.

Abacavir and HLA-B*57:01 is an example of a well-established HLA-HDR association exceptionally well
studied at the molecular/mechanistic level. Abacavir binds noncovalently to the HLA-B*57:01 peptide-binding
cleft, thereby causing conformational changes in the self-peptide-binding motif and inducing a primary immune
response, as per the altered peptide repertoire model [19].
Frequencies of HLA alleles involved in pharmacogenomic associations among the GME
populations
The complete list of pharmacogenomic associations involving HLA alleles is regularly updated and available on the
Pharmacogenomics Knowledge Base website with assigned ratings indicating their ’strength of evidence’ (www.ph
armgkb.org/) [20]. Well-characterized pharmacogenomic associations were extracted from the Pharmacogenomics
Knowledge Base; only associations with clinical annotations and levels of evidence from 1 to 2, considered as
associations with moderate/robust data, were considered for the genes of HLA class I (HLA-A, -C and -B) and
HLA class II (HLA-DRB1, HLA-DQA1 and HLA-DPB1) (Figure 2).
The authors reviewed the prevalence of these alleles in different populations of the GME (Table 1). Highresolution genotyping to determine the frequencies of different HLA alleles have been completed by previous studies
for different populations in the GME, including HLA alleles reported to be involved in HLA-HDR associations.
Closely related alleles, not discriminated by two-field typing, may have a completely different impact over a specific
adverse reaction. Therefore, the authors reported only allele frequencies of HLA alleles determined with two-field
high-resolution HLA genotyping. Table 1 summarizes the prevalence of HLA alleles, class I (HLA-A, HLA-C
and HLA-B) and class II (HLA-DP, HLA-DR and HLA-DQ), involved in well-characterized pharmacogenomic
associations, as determined in the different populations of the GME [74]. For HLA allele frequencies in the
populations of the GME, the authors referred to the HLA allele frequencies database [9], systematic reviews and
published peer-reviewed articles, as inserted in the table within each reported frequency.
Cutaneous adverse reactions, DRESS or TEN syndromes have been recurrently reported as drug reactions after
allopurinol and antiepileptic drug treatment in Moroccan, Tunisian, Iranian and Emiratis patients [21–26]. However,
a limited number of studies have addressed HLA-HDR associations in the region. A case–control study showed a
significant association between HLA-A*31:01 allele and DRESS induced by carbamazepine in a Tunisian cohort [27].
Associations between HLA-DQB1*03:02 and HLA-DRB1*04 and aspirin-exacerbated respiratory disease, as well as
the study of HLA-B*57:01-abacavir hypersensitivity reaction in a small cohort, have been reported from Iran [28,29].
The limited number of studies (based on thorough research in PubMed and Google Scholar, combining different
keywords such as MHC, HLA, drug and hypersensitivity and names of populations and countries) contrasts with
the diversity and the distinctiveness of populations in the region. Gene candidate studies or genome-wide association
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1A

1A

2A

2A

Carbamazepine
Phenytoin
Oxcarbazepine
sulfamethoxazole/
trimethoprim

Carbamazepine

Carbamazepine

Carbamazepine

B*40:01

B*15:11

A*31:01

B*15:02

B*57:01

HLA allele

SJS, TEN

SJS, TEN

DRESS, MPE, SJS,
TEN

SJS, TEN

Drug
hypersensitivity,
DRESS

Adverse drug
reaction(s)

TUN: 1.5% (100)
LYB: 0.8% (118)
Mor-ch: 1.4% (98)

No data or research

No data or research
SUD: 1% (200)

No data or research
JOR: 0.3% (146)

Saudi: 0.3% (105)
UAE: 0.6% (373)

No data or research

UAE-Abu D: 2.8% (52)

SAU: 4.11% (105)

UAE-Abu D: 0.9% (52)

UAE: 0.6% (373)

UAE-Abu D: 0.9% (52)

SAU: 1.43% (105)

OMAN: 2.5% (118)

JOR: 1.7% (146)

No data or research

JOR: 1% (146)

Arabian Peninsula

Mor-ch: 2% (98)

SUD: 3% (200)

No data or research

SUD: 1.5% (200)

Levant

LYB: 5% (118)

TUN: 0.4% (376)

No data or research

Mor-ch: 2.7% (98)

LYB: 0.8% (118)

TUN: 3% (100)

Northeast Africa

Allele frequency, % (sample size)
Northwest Africa

No data or research

No data or research

Pak-Sindhi: 4.4%
(101)

PAK-BAL: 0.8% (66)

IRAN-Bal: 2.2%
(100)

No data or research

IRAN-Bal: 1% (100)

Pakistan and Persia

[68,70,71,76,78,80]

[76,78]

[70,76]

[68,71,76,77,79]

[76]

[76]

[78]

[70,76]

[68,71,76,77]

Ref.

PharmGKB levels of evidence for clinical annotations. The table includes only associations with levels of evidence from 1 to 2, considered as associations with robust data to moderate evidence of an association, as per the PharmGKB. Only
one association with a level of evidence 3 has been included, as it was reported as a US FDA pharmacogenomic biomarker in drug labeling. When there is no mention of the frequency of one population, it means that no studies were
found reporting the prevalence in this population.
ALG: Algerians; BAH: Bahraini; DRESS: Drug reaction with eosinophilia and systemic symptoms; EGY: Egyptian; IRAN-Bal: Iranian-Baloch; JOR: Jordanian; KWA: Kuwaiti; LEB: Lebanese; LYB: Lybian; LYB-Jews: Lybian Jewish; MPE: Maculopapular
exanthema; MOR: Moroccan; Mor-ch: Moroccan Chaouya; OMAN: Omani; PAK-BAL: Pakistan-Baloch; Pak-Sindhi: Pakistan-Sindhi; PAL: Palestinian; PharmGKB: Pharmacogenomics Knowledge Base; SAU: Saudi; SJS: Stevens–Johnson
syndrome; SUD: Sudanese; TEN: Toxic epidermal necrolysis; TUN: Tunisian; UAE: Emiratis; UAE-Abu D: Emiratis Abu Dhabi; YEM-Jews: Yemenite-Jews.

1A

PharmGKB
level of
evidence

Abacavir

Drug

Table 1. A. Frequency of known HLA allele associations with drug hypersensitivity in the populations of the Greater Middle East.
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2B

2B

2A

2A

2A

2B

2B

Allopurinol

Allopurinol

Sulfamethoxazole/
trimethoprim

Dapsone
sulfamethoxazole/
trimethoprim

Methazolamide

Methazolamide

Aspirin

DPB1*03:01

C*01:02

B*59:01

B*13:01

B*38:02

C*03:02

A*33:03

B*58:01

Asthma

SJS, TEN

SJS, TEN

Drug
hypersensitivity,
DRESS, SJS, TEN

SJS, TEN

SJS, TEN

Drug
hypersensitivity, SJS

SJS, DRESS, TEN

TUN: 13.9% (100)

No data

No data

TUN: 0.1% (376)

No data

TUN: 1% (100)

SUD: 10.5% (200)

No data

No data

SUD: 0% (200)

No data

SUD: 0.5% (200)

No data

No data

No data

No data

No data

JOR: 6% (146)

No data

UAE-Abu D: 4.8% (52)

No data

No data

No data

SAU: 1.5% (105)
UAE-Abu D: 4.8% (52)

UAE- Abu D: 4.8% (52)

SAU: 3.48% (105)

UAE-Abu D: 4.8% (52)

OMAN: 2.1% (118)

No data

JOR: 1.3% (146)

Mor-ch: 1.4% (98)

SUD: 2.5% (200)

SUD: 4.5% (200)

LYB: 3.3% (115)

TUN: 5% (100)

TUN: 2% (376)
LYB: 3.3% (118)
Mor-ch: 3.4% (98)

No data

IRAN-Bal: 4.7%
(100)

No data

No data

No data

IRAN-Bal: 4.7%
(100)

Pak-Sindhi: 7.6%
(101)

PAK-bal: 12.7% (66)

IRAN-Bal: 5.6%
(100)

IRAN-Bal: 4% (100)

[76,80]

[76,77]

[76,79]

[68,71,76,77]

[76,78]

[9,70,76]

[68,76,77,80]

[70,71,76–79]

PharmGKB levels of evidence for clinical annotations. The table includes only associations with levels of evidence from 1 to 2, considered as associations with robust data to moderate evidence of an association, as per the PharmGKB. Only
one association with a level of evidence 3 has been included, as it was reported as a US FDA pharmacogenomic biomarker in drug labeling. When there is no mention of the frequency of one population, it means that no studies were
found reporting the prevalence in this population.
ALG: Algerians; BAH: Bahraini; DRESS: Drug reaction with eosinophilia and systemic symptoms; EGY: Egyptian; IRAN-Bal: Iranian-Baloch; JOR: Jordanian; KWA: Kuwaiti; LEB: Lebanese; LYB: Lybian; LYB-Jews: Lybian Jewish; MPE: Maculopapular
exanthema; MOR: Moroccan; Mor-ch: Moroccan Chaouya; OMAN: Omani; PAK-BAL: Pakistan-Baloch; Pak-Sindhi: Pakistan-Sindhi; PAL: Palestinian; PharmGKB: Pharmacogenomics Knowledge Base; SAU: Saudi; SJS: Stevens–Johnson
syndrome; SUD: Sudanese; TEN: Toxic epidermal necrolysis; TUN: Tunisian; UAE: Emiratis; UAE-Abu D: Emiratis Abu Dhabi; YEM-Jews: Yemenite-Jews.
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2B

2A

2B

2B

Lapatinib

Nevirapine

Nevirapine

Nevirapine

DRB1*01:01

C*04:01

B*35:01

DQA1*02:01

DRB1*07:01

Drug
hypersensitivity

DRESS, SJS, TEN

Drug
hypersensitivity

Drug-induced liver
injury

Drug-induced liver
injury

ALG: 1.5% (100)
TUN: 0.6-2% (376–100)
LYB: 0.4% (118)
MOR: 2% (96)
Mor-ch: 1% (98)

TUN: 11.6% (100)
Mor-ch: 12% (98)

Mor-ch: 3.4% (98)

TUN: 4.8% (100)

ALG: 12.25% (106)
TUN: 17.2% (100)
MOR: 12.6% (96)
Mor-ch: 18% (98)

LYB: 17% (118)
LYB-Jews: 19% (119)
ALG: 13-16% (100–97)
TUN: 19%, 20% (376,
100)
MOR: 12.3% (96)
Mor-ch: 16% (98)

EGY: 0% (121)
SUD: 0% (200)

SUD: 13.5% (200)

SUD: 4.3% (200)

No data

EGY: 9% (121)
SUD: 7.8% (200)

JOR: 3.8% (146)
LEB: 5.8% (95)
PAL: 2.3% (109)

JOR: 10% (146)

JOR: 0.3% (146)

JOR: 26.9% (146)
PAL: 12.8% (109)

JOR: 26.9% (146)
LEB: 6.3%, 8.8%
(95, 563)
PAL: 12.7% (109)

BAH: 1.4% (72)
SAU: 0.6% (105)
UAE-Abu D: 0.9% (52)
YEM-Jews: 1.3% (76)

BAH: 14.9% (72)
SAU: 7.9% (105)
UAE-Abu D: 14.4% (52)

UAE-Abu D: 3.8% (52)

KWA: 10.7% (78)
YEM-Jews: 22.1% (76)

SAU: 26.6% (105)
BAH: 9% (72)
UAE-Abu D: 14.4% (52)
YEM-Jews: 22.1% (76)

Iran: 5.5% (100)
IRAN-Bal: 15% (100)

IRAN: 15.4% (120)
IRAN-Bal: 28.6%
(100)

IRAN-Bal: 8.1%
(100)

IRAN-Bal: 3.5%
(100)
Iran: 21.6% (58)

IRAN: 9.1% (100)
IRAN-Bal: 3% (100)

[68,70–72,76–83]

[68,71,72,76–78]

[78]

[71,76,77,80]

[71,76–78,80–82,84]

[68–72,76–83]

PharmGKB levels of evidence for clinical annotations. The table includes only associations with levels of evidence from 1 to 2, considered as associations with robust data to moderate evidence of an association, as per the PharmGKB. Only
one association with a level of evidence 3 has been included, as it was reported as a US FDA pharmacogenomic biomarker in drug labeling. When there is no mention of the frequency of one population, it means that no studies were
found reporting the prevalence in this population.
ALG: Algerians; BAH: Bahraini; DRESS: Drug reaction with eosinophilia and systemic symptoms; EGY: Egyptian; IRAN-Bal: Iranian-Baloch; JOR: Jordanian; KWA: Kuwaiti; LEB: Lebanese; LYB: Lybian; LYB-Jews: Lybian Jewish; MPE: Maculopapular
exanthema; MOR: Moroccan; Mor-ch: Moroccan Chaouya; OMAN: Omani; PAK-BAL: Pakistan-Baloch; Pak-Sindhi: Pakistan-Sindhi; PAL: Palestinian; PharmGKB: Pharmacogenomics Knowledge Base; SAU: Saudi; SJS: Stevens–Johnson
syndrome; SUD: Sudanese; TEN: Toxic epidermal necrolysis; TUN: Tunisian; UAE: Emiratis; UAE-Abu D: Emiratis Abu Dhabi; YEM-Jews: Yemenite-Jews.
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PharmGKB search for classical HLA genes with clinical annotation

HLA class I
(HLA-A, -C, -B)

HLA class II
(HLA-DRB1, -DQA1, -DPB1)

Exclusion of annotation with level 3 and 4

Inclusion of alleles with clinical annotation of level 1 (1A, 1B, 2A, 2B)

HLA-A

HLA-C

HLA-B

HLA-DRB1

HLA-DQA1

HLA-DPB1

A*33:01
A*33:03

C*01:02
C*04:01

B*57:01
B*15:02
B*15:11
B*40:01
B*58:01
B*38:02
B*13:01
B*59:01

DRB1*01:02

DQA1*02:01

DPB1*03:01

Figure 2. Search methodology used in this review to extract HLA alleles with pharmacogenomic associations from
the Pharmacogenomics Knowledge Base website with assigned ratings indicating their ’strength of evidence’ level.
Only associations with clinical annotations and levels of evidence from 1 to 2, considered as associations with
moderate/robust data, were considered for the genes of HLA class I (HLA-A, -C and -B) and HLA class II (HLA-DRB1,
HLA-DQA1 and HLA-DPB1).

studies (GWAS), in GME populations, may identify new associations, or confirm known HLA associations in the
populations of the GME.
Along with the allele prevalence in one population, several other factors are considered when HLA allele
genotyping is to translate into clinical routine. Among these factors are the frequency, the severity of the druginduced reaction, the positive-predictive value (PPV) and negative-predictive value (NPV) of the HLA allele
screening test and the number of patients needed to be tested to prevent one case of hypersensitive reactions
(HSRs). These factors provide information about the efficiency of HLA screening tests in preventing drug reactions
and addressing the cost–effectiveness aspect in a specific population.
HLA carrier frequency is correlated with the prevalence of associated HDRs in the relative population and
therefore may provide a rough guide to the associations that need to be studied in the GME populations. However,
case–control studies are needed to confirm any HLA-HDR association and to define the PPV and the NPV of the
specific allele screening, to address the cost–effectiveness of clinical test screening implementation in the respective
population. The PPV is informing about the extent of additional risk factors, other genetic loci or environmental
factors that may intervene to induce ADRs in patients carrying the HLA allele, and the NPV is informing about the
probability of hypersensitivity reaction based on the absence of HLA allele. Thereafter, the PPV and the NPV are
indispensably required as input parameters to study the cost–effectiveness of an allele screening test in a population,
and they are more informative of the clinical utility of a screening testing than the allele frequency [30].
Abacavir & HLA-associated hypersensitivity

Abacavir is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV infection. Abacavir-induced
hypersensitivity includes fever, generalized rash, fatigue, gastrointestinal symptoms and shortness of breath. HLA-
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B*57:01 is associated with abacavir-induced hypersensitivity. Several independent studies have found abacavir hypersensitivity and HLA-B*57:01 association in North Americans [31], Western Australians [32] and Europeans [33,34].
The PREDICT-1 study, a double-blind, prospective, randomized study including 1956 HIV-infected patients
from 19 countries, confirmed the sensitivity of HLA-B*57:01 as a marker for screening to prevent abacavir hypersensitivity, with an NPV of 100% [33]. However, 82% of the enrolled patients were Caucasians. Later on, the
sensitivity of HLA-B*57:01 as a marker of abacavir hypersensitivity was found in African–American patients with
immunologically confirmed (skin patch) abacavir hypersensitive reaction [35]. Screening for HLA-B*57:01 should
be completed prior to abacavir treatment, as warned on the FDA’s box label, by the EMA [33] and by Clinical
Pharmacogenetics Implementation Consortium guidelines [36].
The prevalence of the HLA-B*57:01 allele, associated with abacavir-induced hypersensitivity, ranges from 1%
to 3% in the GME populations. HLA-B*57:01 has been found to be associated with abacavir hypersensitivity
in Caucasians, African–Americans and Thai populations, where the prevalence of the allele is approximately 6%,
2% and 4%, respectively. In Chinese and Koreans, the prevalence of the allele is 0.8% or lower, justifying their
questioning the benefit of HLA-B*57:01 screening, upon guidelines recommendations, in their relative countries [37].
A very few cases of hypersensitivity to abacavir are detected within a large cohort of HIV patients in these countries,
which did not decrease even after introducing HLA-B*57:01 screening [38]. From the authors’ point of view,
associations involving HLA-B*57:01 deserve to be studied in at least the population of North Africa, as they are
about 3% carriers of the allele, to address the clinical implementation of screening tests before drug use, complying
with the FDA drug warning.
Carbamazepine & HLA-associated hypersensitivity

Carbamazepine is an anticonvulsant that is used to prevent and control seizures. HLA alleles with B75 serotypes,
HLA-B*15:02 and HLA-B*15:11 are predisposing alleles to carbamazepine adverse cutaneous reactions, SJS, TEN,
maculopapular exanthema and DRESS; only Asian populations were found to be a carrier of these alleles, explaining
the FDA statement that their screening before treatment is to be completed in carrier populations or patients with
southeast Asian ancestry. HLA-B*15:02’s strong association with SJS/TEN caused by carbamazepine was reported
first in Han Chinese patients; the study found that 100% SJS patients group carried HLA-B*15:02, whereas
only 3% carried the allele in the tolerant patient group [39]. The association has been confirmed in different
Asian populations, including Chinese, Thai, Korean, Malay, Vietnamese and Indian populations [40–45]. Other
populations, such as Japanese and Caucasians, are low or null carriers of the HLA-B*15:02 allele, which explains
the difficulty of replicating the association in these populations [46,47]. Indeed, the frequency of HLA-B*15:02 is
higher in southeast Asians than in Caucasians and Japanese (2–8% vs <0.1%) [32].
GME populations are not or are lower carriers of these alleles, as they have been rarely reported by studies
achieved in these populations. However, the prevalence of another allele associated with carbamazepine cutaneous
adverse reaction, HLA-A*31:01, associated with HDRs in Caucasians and Asians [47–49], may range from 0.5% to
5% in the GME and may predispose these populations to carbamazepine cutaneous adverse reactions. In Tunisians,
one study found a significant association between HLA-A*31:01 and carbamazepine HDRs [27], confirmed by
a study in a larger cohort. More studies are required to assess the significant association and to determine the
predictive value of HLA-A*31:01 screening in the GME populations in preventing carbamazepine hypersensitivity.
The association is warned on the FDA drug label and its screening in patients of all ancestries is recommended by the
Canadian Pharmacogenomics Network for Drug Safety and the Canadian Department for National Public Health
(Health Canada – Santé Canada) [48,50]. It is worth noting that the HLA-A*02:01 allele, reported in association
with increased risk of maculopapular exanthema induced by carbamazepine and lamotrigine treatment [49,51], has
a prevalence of 17–20% in North African and Middle Eastern populations [52]. This association is not reported in
Table 1, as the related strength of evidence is level 3 and therefore considered an association with a low level of
evidence in the Pharmacogenomics Knowledge Base.
Allopurinol & HLA-associated hypersensitivity

Several alleles have been found to predispose patients to allopurinol-induced SJS and TEN syndromes: HLAB*58:01, HLA-A*33:03 and HLA-C*03:02. Allopurinol is a xanthine oxidase inhibitor used in the first-line
treatment of gout and hyperuricemia.
A strong association between HLA-B*58:01/allopurinol-mediated severe cutaneous adverse reactions, SJS, TEN
and DRESS was found in different populations: Han Chinese, Thais and Koreans [43,53–57]. A weaker but significant
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association was also found in Japanese and Europeans, where the HLA-B*58:01 allele frequency is lower (example:
20% in Han Chinese vs 1–5% in Europeans) [58,59].
The prevalence of HLA-B*58:01 in the GME populations may range from 2% to 5% in North Africans and
Middle Easterners, and 4–5% in those in the Arabic Peninsula and Persians. The Clinical Pharmacogenetics
Implementation Consortium recommends not prescribing allopurinol to patients positive for HLA-B*58:01 and
that negative genotype does not exclude the possibility of HDRs, especially in Europeans [60]. The incidence
of severe cutaneous adverse reactions in the Taiwanese population significantly decreased in patients positive for
HLA-B*58:01 when allopurinol was stopped and an alternative treatment was used [61].
Another HLA allele associated with allopurinol HDRs is HLA-A*33:03, found significantly in Europeans [62].
HLA-A*33:03 in Pakistani populations is reaching 7–12%, which should certainly motivate studying the association
in allopurinol HDR patients.
Nevirapine & HLA drug-associated hypersensitivity

In one study, HLA-C*04:01 was significantly associated with an increased risk of developing cutaneous adverse
reactions and hepatotoxicity hypersensitivity to nevirapine, an antiretroviral therapy. This association was found
to be significant in a number of different ethnic populations: Black Africans, Caucasians and Thais. Its frequency
may range from 8% to 14% in the GME populations or even higher in the Iranian-Baloch population, where
it may reach 28%. HLA-B*35:01 and HLA-DRB1*01:01 are also associated with nevirapine hypersensitivity and
populations of the GME are carriers of these alleles. As HLA-C*04:01, HLA-B*35:01 and HLA-DRB1*01:01 are
in linkage disequilibrium, reported associations could be haplotype dependent rather than allele dependent [63].
Lapatinib & HLA-associated hepatotoxicity

Lapatinib is a tyrosine kinase inhibitor used in combination therapy for advanced or metastatic HER2-positive
breast cancer. HLA-DRB1*07:01 carriage is significantly associated with serum alanine aminotransferase elevation
in lapatinib-treated patients. These HLA alleles are present in approximately 15–25% of Caucasian, Asian, African
and Hispanic populations and 1% in Japanese populations. Their prevalence may range from 10% to 25 % in the
GME. The FDA statement on the lapatinib drug label is that liver function should be monitored in all patients
receiving lapatinib therapy, regardless of genotype.
Aspirin & HLA-associated asthma

HLA-DPB1*03:01 is carried by ∼10% and 14% of Sudanese people and Tunisians, respectively, and has been
strongly associated with aspirin-induced asthma in asthmatic patients. The association has been found in the White
Polish population and Koreans, and further studies will be needed to replicate the finding in different populations
and to investigate other HLA alleles in linkage disequilibrium with the HLA-DPB1*03:01 allele [64,65].
Cost–effectiveness of HLA screening prior to drug use

Cost–effectiveness analysis and health technology assessment aim to achieve better health in ways that the introduced
testing is affordable and acceptable. They evaluate health outcomes relative to monetized input, for better and
efficient allocations of resources in healthcare settings. Different studies have evaluated the cost–effectiveness of
screening HLA alleles robustly associated with HSR in different countries. For example, the cost–effectiveness
analysis of HLA-B*57:01 screening prior to abacavir use was done in the USA [66] and in the UK [34]. An incremental
cost–effectiveness ratio of the HLA-B*57:01 screening test was evaluated at $36,700/quality-adjusted life year when
compared with no testing in the USA, and €22.811 per hypersensitivity reaction avoided in the UK. Based on
the results of these studies, the HLA-B*57:01 screening test was considered cost effective for the relative countries,
considering the prevalence, the PPV, the NPV and the threshold of cost–effectiveness relative to the USA and UK.
In Indonesia, the screening of HLA-B*15:02 prior to carbamazepine treatment was evaluated and found not to
be cost effective [67]. Along with the allele prevalence in one population, the PPV and the NPV are indispensably
required as input parameters to study the cost–effectiveness of an allele screening test in a population; this should
motivate more studies in the GME populations in the particular case of HLA presenting high variability across
ethnicities.
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Conclusion
We summarized the frequency of significant HLA alleles associated with HDRs induced by different drugs reported
mainly by studying Western and Asian populations, in different populations of the GME. Regarding the lack
of studies of association from the GME populations, our review intended to motivate researchers to undertake
gene candidate studies or GWASs in these populations. We underscore the need to study associations with HLA
alleles presenting high prevalence, such as HLA-A*33:03, associated with allopurinol HDRs (12.7% in Pakistan);
HLA-DPB1*03:01, associated with aspirin-induced asthma in North Africa (13.9%); and HLA-A*31:01, associated
with carbamazepine in North Africa, where the prevalence may reach 5%. We mentioned that HLA-A*02:01 has
been associated with the increased risk of maculopapular exanthema induced by carbamazepine and lamotrigine; the
association should be studied in the GME populations where the prevalence ranges from 17 to 20% to be confirmed.
Gene candidate studies or GWASs, in GME populations, may discover new associations or confirm associations
with a low level of evidence involving HLA alleles carried more frequently in the populations of the GME than
in other populations. The advent of next-generation sequencing (NGS), a high-throughput sequencing technique,
has brought many advancements to HLA profiling, providing higher resolution of HLA genotyping. The scalability
of NGS and the various bioinformatic tools that have been developed to achieve HLA genotyping provide an
interesting opportunity to reduce the knowledge gap in the characterization of HLA-HDR associations in the
GME populations. Among the studies that we referred to in our review, HLA genotyping to determine HLA
allele frequencies has conducted by NGS in Saudi Arabians [68], while it has been conducted using sequencespecific oligonucleotide probes or sequence specific primer for most of the different other studies on the GME
populations [69–72]. In Middle East/North African countries, HLA genotyping with NGS has been used for other
applications – for example, to study allele association to severe COVID-19 infection in the UAE [73].
Despite a considerable number of discovered HLA allele associations, the transition into clinical practice has
been made only for a few, well-characterized associations. Many challenges, such as the rarity of hypersensitivity
reactions and the high ethnic variability over the world, slow down the pace of the progress. Discovering new
associations by studying GME populations could improve the outcome of patients belonging to these populations
and overall may improve the efficiency of screening by tagging HLA alleles of different ethnicities associated with
ADRs [75]. Consortium efforts and clinical networks with the largest involvement of professionals from the GME
region would advance discoveries and would have a clinical impact on avoiding severe drug reactions.
Future perspective
HLA-HDR pharmacogenomic associations are very rarely studied in the GME populations. Gene candidate studies
or GWAS, in GME populations, may discover new associations or confirm associations reported with a low level
of evidence. The advent NGS and the scalability of the various bioinformatic tools that have been developed to
achieve HLA genotyping provide an interesting opportunity to reduce knowledge gap in the characterization of
HLA-HDR associations in the GME-populations. Further studies genotyping HLA and further studies identifying
pharmacogenomic markers are expected in the near future from the GME, particularly in the populations where
genomic projects are ongoing. The high ethnic variability of HLA genes should particularly motivate studying
HLA-HDRs pharmacogenomic associations in different populations of the GME.

Executive summary
Adverse drug reactions could be life threatening, particularly type B hypersensitivity drug reactions (HDRs).
HDRs are associated with specific alleles of the HLAs.
Most of the discovered associations were based on studies including populations from Asia and Western countries.
The high ethnic variability of HLA genes should particularly motivate the study of HLA-HDR pharmacogenomic
associations in different populations of the world.
• Genome wide association and case–control studies would confirm known associations and allow for the discovery
of new pharmacogenomic markers in the Greater Middle East populations where HLA-drug hypersensitivity has
been rarely studied.
• Only the study and the confirmation of any HLA-HDR associations in a specific population allow the
cost–effectiveness evaluation of screening the allele, in this population, before drug use.
•
•
•
•
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